To establish the involvement of FOSL2 in disease aggressiveness, we performed differentially gene expression analysis comparing poor and better outcome entities as well as FOSL2high and FOSL2low tumors using data from all 27 cancer entities. This evidence concerns the gene FOSL2 and cancer.